Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
289.9 USD | +1.57% | +3.46% | -10.31% |
08/05 | UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating | MT |
08/05 | RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.31% | 8.11B | |
-5.58% | 182B | |
+2.00% | 111B | |
-3.31% | 68.48B | |
+0.52% | 49.69B | |
+7.98% | 44.46B | |
+2.33% | 40.67B | |
+22.72% | 31.22B | |
+1.81% | 26.09B | |
+15.30% | 25.32B |
- Stock Market
- Equities
- BIO Stock
- News Bio-Rad Laboratories, Inc.
- Credit Suisse Initiates Coverage of 20 Companies in Life Science Tools, Services, Diagnostics Sectors; Outperform-Rated Bio-Rad, IQVIA, Bipo-Techne, Natera Named Top Picks